

December 11, 2013



# Merriman Capital to Host Pressure BioSciences, Inc. Investor Call at 4:30 p.m. EST on Thursday, December 12, 2013

SOUTH EASTON, Mass., Dec. 11, 2013 /PRNewswire/ --Pressure BioSciences, Inc. (OTCQB: P BIO) ("PBI" or the "Company") today announced that Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), will host an investor call for PBI on Thursday, December 12, 2013 at 4:30 p.m. EST. Pressure BioSciences CEO Richard T. Schumacher and Board Chairman Jeffrey N. Peterson will provide an update on the Company, including a review of the achievements of 2013 and stated goals for 2014, via a webcast with an accompanying PowerPoint presentation.

All investors and interested parties are welcome to join the conference call and webcast. A question and answer session will follow the opening remarks and presentation. Mr. Schumacher, Mr. Peterson, and board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will be available during the Q&A session.

## Conference Call, Webcast and Presentation Information

Date: Thursday, December 12, 2013  
Time: 4:30 PM Eastern Standard Time (EST)

To listen to this teleconference via telephone (whether or not watching the webcast):  
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)  
Passcode: VS87265    Conference ID: 865561

To view the webcast, use the following conference link (NOTE: you must use the call-in number above for the audio portion of the webcast):  
<http://www.join.me/pbio.investormeeting.M1>.

The P BIO presentation will be available for viewing and downloading as of 10 a.m. EST, Thursday, December 12, 2013 on the Company's website:  
<http://www.pressurebiosciences.com>.

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company's website for 30 days.

## About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: P BIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated \$6 billion life sciences sample

preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

### **About Merriman Capital, Inc.**

Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, as well as Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is a leading advisory firm for publicly traded, high-growth companies.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) <http://www.finra.org/> and the Securities Investor Protection Corporation (SIPC) <http://www.sipc.org/>.

### **Forward Looking Statements**

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

Please visit us on: Facebook, LinkedIn, and Twitter.

<http://www.pressurebiosciences.com>

### **Investor Contacts:**

Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.  
230-1828 (T)

(508)

Douglas Rogers, Managing Director, Merriman Capital, Inc.  
248-5612 (T)

(415)

SOURCE Pressure BioSciences, Inc.